Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication
Authors:
- 1 November 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 202 (5) , 936-943
Abstract
Shared patient-physician decision-making regarding treatment for prostate cancer detected by prostate-specific antigen screening involves a complex calculus weighing the risk of the cancer and patient life expectancy. We investigated quantifying these competing risks using the probability that the cancer was “overdiagnosed”—i.e., would not have been clinically diagnosed (diagnosed without screening) during the patient’s remaining lifetime. Using an established model of prostate cancer screening and clinical diagnosis, we simulated screen-detected cases and determined whether modeled clinical diagnosis would occur before non-cancer death, which was based on comorbidity-adjusted population lifetables. Logistic regression models were fitted to the simulated data and used to estimate overdiagnosis probabilities given patient age, PSA level, Gleason sum, and comorbidity category. An online calculator was developed to communicate overdiagnosis estimates; face validity and ease of use was assessed by surveying 32 clinical experts. Estimated probabilities of overdiagnosis ranged 4%−78% across clinicopathologic variables and comorbidity status. Ignoring comorbidity, the estimated probability for a 70-year-old man with PSA 9.4 ng/mL and Gleason 6 is 34%; if he has severe comorbidities, the estimate increases to 51%, a personalization that may help inform the choice between active surveillance and definitive treatment. Based on responses from 20/32 experts, we modified the online calculator’s explanation of overdiagnosis and input method for comorbid conditions. The probability of overdiagnosis is strongly influenced by comorbidity status in addition to age. Personalized estimates incorporating comorbidity may contribute to shared decision-making between patients and providers regarding personalized treatment selection.Keywords
This publication has 24 references indexed in Scilit:
- Assessing Non–Cancer-Related Health Status of US Cancer Patients: Other-Cause Survival and Comorbidity PrevalenceAmerican Journal of Epidemiology, 2013
- Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening StrategiesAnnals of Internal Medicine, 2013
- How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer?Canadian Urological Association Journal, 2012
- Calibrating disease progression models using population data: a critical precursor to policy development in cancer controlBiostatistics, 2010
- Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trialBJU International, 2008
- Numeric, Verbal, and Visual Formats of Conveying Health Risks: Suggested Best Practices and Future RecommendationsMedical Decision Making, 2007
- Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview SurveyCancer, 2007
- Prostate cancer detection with two sets of ten-core compared with two sets of sextant biopsiesUrology, 2001
- A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy.2000
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987